Vera Therapeutics, Inc. (VERA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $36.02: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 7.50; Below-average business quality.
Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc fusion protein targeting BAFF and APRIL) for IgAN. A BLA was submitted November 2025 with priority review granted and PDUFA date July 7, 2026. The company had $714.6M in cash as of December 31, 2025... Read more
Sell if holding. Engine safety override at $36.02: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 7.50; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineproduct candidates10-K Item 1A: 'We are substantially dependent on the success of our product candidates.'
Material Events(8-K, last 90d)
- 2026-03-09Item 5.02LOWChristopher Hite appointed to Board as Class III Director effective March 5, 2026. Granted initial stock option for 24,937 shares at $38.85. Routine board expansion; no departure involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $36.02: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 7.50; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $34.60. Score 4.8/10, moderate confidence.
Take-profit target: $68.73 (+91.0% upside). Prior stop was $34.60. Stop-loss: $34.60.
Concentration risk — Pipeline: product candidates; Quality below floor (1.6 < 4.0).
Vera Therapeutics, Inc. trades at a P/E of N/A (forward -11.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover VERA with a consensus score of 4.3/5. Average price target: $79.
What does Vera Therapeutics, Inc. do?Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc fusion protein targeting BAFF and...
Vera Therapeutics is a late clinical-stage biotech developing atacicept (TACI-Fc fusion protein targeting BAFF and APRIL) for IgAN. A BLA was submitted November 2025 with priority review granted and PDUFA date July 7, 2026. The company had $714.6M in cash as of December 31, 2025 and has never generated product revenue.